Search Results
Your search for The ASCO matches 22544 pages
Showing 1 - 50Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline. “The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) recently approved daraxonrasib, (Rasonque), a multiselective RAS(ON) inhibitor, for treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. ...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money. In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
ESMO Announces 2026 Society Award Recipients
The European Society for Medical Oncology (ESMO) has announced the recipients of the 2026 ESMO Society Awards, recognizing four outstanding oncology professionals whose contributions have advanced cancer research, enhanced clinical care, and strengthened the global oncology community. ESMO Award...
SUO/AUA Updates Guidelines for Non–Muscle Invasive Bladder Cancer
The American Urologic Association (AUA), in partnership with the Society of Urologic Oncology (SUO) has released an amendment for 2026 to the Diagnosis and Treatment of Non–Muscle Invasive Bladder Cancer (NMIBC) Guideline, published in The Journal of Urology. The amendment introduces 40 new and...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Prostate Cancer: Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Patients with nonmetastatic prostate cancer who consumed higher quantities of saturated fats, including animal fats, had a higher risk of all-cause mortality, including death from cardiovascular disease and other cancer, according to the results of a study published in JAMA Network Open. “Our...
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
In addition to searching for breast cancer, artificial intelligence (AI) used in mammography reads may help to detect common cardiovascular diseases, according to study findings presented at the ESC Congress 2026. “Because mammography is already widely used, analyzing the same images for...
Prostate Cancer: Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in JACC: CardioOncology and presented at the ESC Congress 2026. “The major findings...
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published by Chang et al in Blood Advances. But the gains have not reached...
Researchers Define Molecular, Prognostic Subgroups in Therapy-Related Myeloid Neoplasms
Identifying germline genetic variants in patients with therapy-related myeloid neoplasms revealed distinct molecular and prognostic subgroups with distinct outcomes, according to research findings published in Blood Advances. The findings could help to guide physicians in determining which patients ...
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
Cancer data for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually combined, hiding vast differences in cancer risk. New disaggregated data analyzed by researchers at the American Cancer Society (ACS) show that Native Hawaiian women have a 27% higher breast cancer...
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated,...
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
The addition of spartalizumab to dabrafenib and trametinib demonstrated a long-term survival benefit in patients with BRAF V600–mutant metastatic melanoma, according to the final overall survival analysis from the phase III COMBI-I trial published in the Journal of Clinical Oncology. “[T]he...
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
Scientists are making progress in developing new cancer treatments, but a patient’s experience with cancer is shaped by more than medicine. A new sociological study has found that conflicting medical, work, and family timelines compound inequality, draining resources and displacing goals for even...
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
The University of Texas (UT) MD Anderson Cancer Center is recognizing the leadership of President Peter WT Pisters, MD, following his announced plan to retire from MD Anderson to focus on the next chapter of his career. The UT System Board of Regents and Chancellor John M. Zerwas, MD, have named...
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Radiation to the thymus was found to be associated with worse outcomes in patients with non–small cell lung cancer (NSCLC), leading to an increased risk of metastasis, according to findings published in the Annals of Oncology. “The thymus is currently not routinely treated as an important organ...
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
For more than a decade, geriatric oncology has evolved from a niche discipline into an evidence-based component of high-quality cancer care. Landmark randomized trials, including the Geriatric Assessment for Patients 70 Years and Older Starting Cancer Treatment (GAP70+) trial,1 the Geriatric...
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
Investigators from Friends of Cancer Research (Friends) recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making. The first article, published by Andrews et al in the Journal of Liquid Biopsy, aggregated data from...
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios...
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Today, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for essential thrombocythemia in nearly 3 decades. Ropeginterferon alfa-2b-njft has been...
Biomarker Guides Treatment Sequencing, Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
Using a blood test to track thymidine kinase activity may help determine optimal first-line treatment for patients with BRAF V600–mutated metastatic melanoma, according to findings published in Clinical Cancer Research. "The results suggest that thymidine kinase activity may help identify which...
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
On August 28, the U.S. Food and Drug Administration (FDA) approved rusfertide (Mimrylo) for the treatment of erythrocytosis in adults with polycythemia vera (PV). Rusfertide is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to...
cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore. In this...
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. The analysis found that, whereas industry trials were more...
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some...
ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation
ASCO joins the oncology community in mourning the death of Harold P. Freeman, MD, a world-renowned expert on and advocate for health equity and the pioneer of patient navigation services in oncology. Dr. Freeman passed away on August 11, 2026; he was 93. After completing medical training at Howard ...
WashU Medicine Appoints New Chief of Head and Neck Surgery
Andrés M. Bur, MD, FACS, has been named Chief of the Division of Head and Neck Surgery in the Department of Otolaryngology–Head & Neck Surgery at WashU Medicine and Co-Director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish...
Cleveland Clinic President Discusses Friday’s AI Summit for Health-Care Professionals
Artificial intelligence (AI) is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, Cleveland Clinic, in collaboration with the College of Healthcare Information Management Executives (CHIME), ...
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
On August 26, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy....
Colorectal Cancer May Cause Peripheral Neuropathy Before Treatment, Preclinical Study Finds
Colorectal cancer may result in tumor-related inflammation that damages peripheral nerves before even starting cancer treatment, according to preclinical findings published in Nature Communications. This damage may be the reason why colorectal cancer survivors are more likely to develop peripheral...
Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82
Gary R. Morrow, PhD, MS, died on July 7, 2026, at age 82, from complications due to pneumonia and a 16-year history of prostate cancer, according to an obituary shared by his family. Over nearly 5 decades at the University of Rochester Wilmot Cancer Institute, Dr. Morrow brought in $100 million in ...
Research Finds Supercentenarians Have an Abundance of Cancer-Killing Immune Cells
The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. These cells multiply in a process called clonal expansion to help fight infection. In a study published by Hashimoto in Cell Reports, researchers...
ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS
ASCO joins the oncology community in mourning the death of Gary R. Morrow, PhD, MS, who passed away on July 7, 2026; Dr. Morrow was 82. Dr. Morrow was a pioneer in the field of supportive care, and his research on the potentially debilitating side effects of cancer treatment, including nausea,...
FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer
On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including: in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra), as first-line treatment for adults with HER2-positive...
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
To be a mid-career oncologist is to occupy an emotionally and physically taxing space within a trying clinical environment. We may be 10 years and beyond our post-training. We are no longer trainees who may be protected by institutional shields, nor are we established senior department heads with...
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study,...
Phase III OPTIMA Trial: Many Patients With ER-Positive, HER2-Negative Breast Cancer May Be Able to Avoid Chemotherapy
New results from the international, randomized, phase III OPTIMA trial indicate that select patients with clinically high-risk, estrogen receptor–positive, HER2-negative early breast cancer who have a low risk of recurrence based on tumor gene expression testing may be able to safely avoid...
Cancer Epidemiologist Joseph F. Fraumeni, Jr, MD, Dies at 93
The oncology community is mourning the loss of renowned physician-scientist and cancer epidemiologist Joseph F. Fraumeni, Jr, MD, who died on June 22, 2026, at the age of 93. During a career spanning more than 5 decades at the National Cancer Institute (NCI), Dr. Fraumeni fundamentally changed the...
Living Guideline Adds Repotrectinib and Zongertinib as Treatment Options for Advanced NSCLC With Driver Alterations
ASCO has issued a new update to its Living Guideline on therapy for stage IV non–small cell lung cancer (NSCLC) with driver alterations, including new recommendations for two therapies: repotrectinib, a ROS1 tyrosine kinase inhibitor (TKI), and zongertinib, a HER2-selective, EGFR-sparing TKI.1 The...
Lori J. Pierce, MD, FASCO, Named Distinguished University Professor, University of Michigan
University of Michigan (U-M) Professor Lori J. Pierce, MD, is one of six U-M faculty members recognized for their outstanding teaching and service with one of the university’s prestigious honors, the Distinguished University Professorship. The U-M Board of Regents recently approved the...
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
The U.S. Food and Drug Administration (FDA) has released a discussion paper regarding factors that go into the regulation of generative artificial intelligence (AI)–enabled medical devices and is asking for public feedback, focusing on areas such as risk assessment, premarket evaluation, and...
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen...
Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced, Refractory Malignancies
Our data on a triplet combination of chemotherapy, immune checkpoint inhibitors, and targeted therapy (ICTriplex) in advanced and refractory malignancies were presented in June at the 2026 ASCO Breakthrough Conference in Singapore. ICTriplex is a therapeutic strategy; it is not a single specific...
Study Supports Personalized Weight-Loss Intervention for Breast Cancer Survivors
A personalized approach to obesity treatment may help breast cancer survivors improve their long-term health by identifying early which patients need more than behavioral lifestyle intervention alone. The phase II Adaptive Nutrition and Exercise Weight Loss (A-NEW) trial found that breast cancer...
